Wastewater-based epidemiology (WBE) was a near-real-time monitoring strategy for illegal drugs. However, solid-phase extraction (SPE) widely used in WBE was time-consuming and labor-intensive to extract ultra-trace target compounds from wastewater. In this study, a convenient magnetic solid-phase extraction (MSPE) approach based on newly designed and synthesized polydopamine functionalized core-shell magnetic mesoporous silica (Fe₃O₄@nSiO₂@mSiO₂@PDA) nanocomposite was synthesized and firstly utilized for simultaneously extracting five amphetamine-type stimulants (ATSs) from wastewater samples. Subsequently, ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method coupled with optimal MSPE was developed for determination of ultra-trace ATSs in wastewater. The validation results indicated a favorable linearity ranging from 1 to 200 ng L^-1, low limit of detection (0.5-2.5 ng L^-1), and qualified recovery (95.1-106.6%) and repeatability (0.6-6.2%). In addition, the Fe₃O₄@nSiO₂@mSiO₂@PDA nanoparticles could be reused for at least ten times without significant loss of the adsorption efficiencies of ATSs. Finally, the MSPE-UPLC-MS/MS method was successfully applied to real wastewater samples with the results that the preparation procedure was shrunk from 2 h to 30 min without obvious decline of extraction efficiency compared with the SPE. Hence, based on merits of the novel Fe₃O₄@nSiO₂@mSiO₂@PDA nanocomposite, the proposed method is convenient and reliable for determination of ATSs in wastewater.

Polo-box domain of polo-like kinase 1 (PLK1-PBD) has a pivotal role in cell proliferation and could be implicated as a potential anticancer target. Although some small-molecule inhibitors have been developed, their clinical application has been restricted by the poor selectivity. Therefore, there is an urgent need to develop effective PLK1-PBD inhibitors. Herein, we have developed a virtual screening protocol to find PLK1-PBD inhibitors by using combination of structure-based pharmacophore modeling and molecular docking. This protocol was successfully applied to screen PLK1-PBD inhibitors from specs database. MTT assay indicated that five screened hits suppressed the growth of HeLa cells. Particularly, hit-5, as a selective PLK1 inhibitor targeting PLK1-PBD, significantly inhibited the progression of HeLa cells-derived xenograft, with no obvious side effects. This work demonstrates that hit-5 may be a potential anticancer agent.